Prioritizing Health Care: Reform Gains Early Momentum
This article was originally published in RPM Report
Executive Summary
Health care reform advocates think the stars are aligned for a major push toward universal coverage under President-elect Barack Obama. They aren’t about to let the free-falling economy get in the way.
You may also be interested in...
Obamacare: The Politics of Health Care Reform Entering the Endgame
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
Biopharma in 2008: What a Difference an Economic Crisis Makes
Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.
The Value of Options: CBO Health Reform Pre-Scores Draw Yawn From Wall Street
The Congressional Budget Office released a book of budget options on over 100 single health reform proposals. Analysts say it’s too early for them to start paying attention. But if recent history provides any lesson, it’s that how CBO scores health reform matters greatly to its overall legislative prospects—and the impact on Wall Street.